Zanganeh Mahkam 4
4 · Summit Therapeutics Inc. · Filed Oct 23, 2025
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2025-10-21$18.74/sh+26,680$499,983→ 76,680 total(indirect: Immediate family member) - Award
Common Stock
2025-10-21$18.74/sh+266,808$4,999,982→ 25,724,474 total(indirect: By Trust) - Award
Common Stock
2025-10-21$18.74/sh+13,980,789$261,999,986→ 570,073,879 total(indirect: By Spouse)
Holdings
- 10,199,776(indirect: By Trust)
Common Stock
- 31,000
Common Stock
Footnotes (2)
- [F1]Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.